ERBB2 and breast cancer: Moreover, since the KATHERINE trial results [40], patients with HER2-positive BC with pathologic invasive residual disease at surgery after standard preoperative chemotherapy and HER2-targeted therapy should be offered 14 cycles of adjuvant TDM1 [41].